NCT07376109 Effects of Infertility and Assisted Reproductive Technology on Sexual Function and Behavior
| NCT ID | NCT07376109 |
| Status | Recruiting |
| Phase | — |
| Sponsor | McGill University Health Centre/Research Institute of the McGill University Health Centre |
| Condition | Infertility Assisted Reproductive Technology |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2026-02-06 |
| Primary Completion | 2027-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2026-02-06 with a primary completion date of 2027-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This cross-sectional observational study examines how infertility and the use of assisted reproductive technology (ART) are related to sexual function and sexual behaviors in women seeking fertility treatment. Infertility and the stress of ART may be associated with changes in sexual desire, satisfaction, and activity. The purpose is to better understand these associations to support the sexual health and overall well-being of women undergoing fertility care. Women who are assigned female at birth, under 45 years old, diagnosed with infertility, and attending appointments at the MUHC Reproductive Centre are invited to take part. Participants will be asked to complete an anonymous questionnaire while waiting for their clinical visit. The questionnaire includes the validated Female Sexual Function Index (FSFI), which measures different aspects of sexual function, and additional questions about sexual activities, such as frequency of intercourse and other behaviors before and after fertility treatments. Participants will not provide any identifying information. Completed questionnaires will be placed in a secure collection box to protect confidentiality. Data from approximately 500 participants will be analyzed to explore how infertility type (primary vs. secondary), duration of infertility, and the number of unsuccessful ART cycles relate to sexual function and behavior. Findings from this study may help healthcare providers better recognize and address the sexual health concerns of women with infertility. This study is approved by the McGill University Health Centre Research Ethics Board (REB #2025-11459).
Eligibility Criteria
Inclusion Criteria: 1. Assigned female at birth. 2. Self-identify as a woman. 3. Age 18-44 years. 4. Diagnosis of infertility. 5. Seeking fertility treatment at the MUHC Reproductive Centre. Exclusion Criteria: 1. Assigned male at birth. 2. Age 45 years or older. 3. Sexual practices that do not allow for the possibility of conception (e.g., same-sex relationships without use of assisted reproductive technologies). 4. Seeking oocyte cryopreservation. 5. Individuals who do not wish to complete the anonymous questionnaire.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07376109 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 44 Years, studying Infertility Assisted Reproductive Technology. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07376109 currently recruiting?
Yes, NCT07376109 is actively recruiting participants. Contact the research team at rebecca.eckler@mail.mcgill.ca for enrollment information.
Where is the NCT07376109 trial being conducted?
This trial is being conducted at Montreal, Canada.
Who is sponsoring the NCT07376109 clinical trial?
NCT07376109 is sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. The trial plans to enroll 500 participants.